Hyaluronic Acid vs. Simple Emollient for the Management of Radio-induced Early Skin Toxicity: Results of an Open-label, Phase III Trial

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2010.07.1484 ◽

2010 ◽

Vol 78 (3) ◽

pp. S637 ◽

Author(s):

Y.M. Kirova ◽

I. Fromantin ◽

Y. de Ricke ◽

M.A. Bollet ◽

E. Morvan ◽

...

Keyword(s):

Hyaluronic Acid ◽

Skin Toxicity ◽

Phase Iii ◽

Phase Iii Trial ◽

Open Label Phase

Download Full-text

379 Hyaluronic acid versus simple emollient for the management of radio-induced skin toxicity: results of an open-label, phase III trial

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(10)70405-5 ◽

2010 ◽

Vol 8 (3) ◽

pp. 168

Author(s):

Y.M. Kirova ◽

I. Fromantin ◽

Y. de Rycke ◽

M.A. Bollet ◽

E. Morvan ◽

...

Keyword(s):

Hyaluronic Acid ◽

Skin Toxicity ◽

Phase Iii ◽

Phase Iii Trial ◽

Acid Versus ◽

Open Label Phase

Download Full-text

Abstract OT-01-02: Adaptlate -a randomized, controlled, open-label, phase-iii trial on adjuvant dynamic marker - adjusted personalized therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high risk, hr+/her2- early breast cancer

10.1158/1538-7445.sabcs20-ot-01-02 ◽

2021 ◽

Author(s):

Oleg Gluz ◽

Tom Degenhardt ◽

Norbert Marschner ◽

Matthias Christgen ◽

Hans Heinrich Kreipe ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Endocrine Therapy ◽

Early Breast Cancer ◽

Adjuvant Endocrine Therapy ◽

Phase Iii ◽

Phase Iii Trial ◽

Randomized Controlled ◽

Open Label Phase

Download Full-text

A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyy097 ◽

2018 ◽

Vol 48 (9) ◽

pp. 855-859 ◽

Author(s):

Yutaka Yamamoto ◽

Hiroji Iwata ◽

Takayuki Ueno ◽

Naruto Taira ◽

Masahiro Kashiwaba ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Phase Iii Trial ◽

Open Label Phase ◽

Previously Treated

Download Full-text

Efficacy and Safety of Carboplatin With Nab-Paclitaxel Versus Docetaxel in Elderly Patients with Squamous-Cell Lung Cancer (CAPITAL): A Randomized, Multicenter, Open-Label, Phase III Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3847741 ◽

2021 ◽

Author(s):

Yoshihito Kogure ◽

Shunichiro Iwasawa ◽

Hideo Saka ◽

Yoichiro Hamamoto ◽

Akiko Kada ◽

...

Keyword(s):

Lung Cancer ◽

Elderly Patients ◽

Squamous Cell ◽

Cell Lung Cancer ◽

Phase Iii ◽

Squamous Cell Lung Cancer ◽

Efficacy And Safety ◽

Phase Iii Trial ◽

Open Label Phase

Download Full-text

Postoperative Adjuvant Anastrozole for 10 Rather than 5 Years in Patients with Oestrogen Receptor-Positive Breast Cancer: AERAS, a Randomised Multicentre Open-Label Phase III Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3918274 ◽

2021 ◽

Author(s):

Takuji Iwase ◽

Shigehira Saji ◽

Kotaro Iijima ◽

Kenji Higaki ◽

Shoichiro Ohtani ◽

...

Keyword(s):

Breast Cancer ◽

Oestrogen Receptor ◽

Phase Iii ◽

Phase Iii Trial ◽

Open Label Phase ◽

Positive Breast Cancer

Download Full-text

Abstract S4-1: FinXX Final 5-Year Analysis: Results of the Randomised, Open-Label, Phase III Trial in Medium-to-High Risk Early Breast Cancer

10.1158/0008-5472.sabcs10-s4-1 ◽

2010 ◽

Author(s):

H Joensuu ◽

P-L Kellokumpu-Lehtinen ◽

R Huovinen ◽

A Jukkola-Vuorinen ◽

M Tanner ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Early Breast Cancer ◽

Phase Iii ◽

Phase Iii Trial ◽

Open Label Phase

Download Full-text

Abstract OT3-05-07: PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2 positive metastatic breast cancer

10.1158/1538-7445.sabcs17-ot3-05-07 ◽

2018 ◽

Author(s):

O Metzger-Filho ◽

S Mandrekar ◽

S Loibl ◽

E Ciruelos ◽

L Gianni ◽

...

Keyword(s):

Endocrine Therapy ◽

Metastatic Breast ◽

Phase Iii ◽

Induction Treatment ◽

Efficacy And Safety ◽

Her2 Positive ◽

Phase Iii Trial ◽

Hormone Receptor Positive ◽

Open Label Phase

Download Full-text

PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)

Annals of Oncology ◽

10.1093/annonc/mdy272.357 ◽

2018 ◽

Vol 29 ◽

pp. viii121 ◽

Author(s):

S. Loibl ◽

O. Metzger ◽

S.J. Mandrekar ◽

C. Mundhenke ◽

S. Seiler ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Induction Treatment ◽

Efficacy And Safety ◽

Her2 Positive ◽

Phase Iii Trial ◽

Hormone Receptor Positive ◽

Open Label Phase

Download Full-text

Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.7500 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7500-7500 ◽

Author(s):

J. Jassem ◽

C. J. Langer ◽

D. D. Karp ◽

T. Mok ◽

R. J. Benner ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Phase Iii ◽

Small Cell Lung ◽

Phase Iii Trial ◽

Open Label Phase

Download Full-text

Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.

Journal of Clinical Oncology ◽

10.1200/jco.2017.35.15_suppl.lba9007 ◽

2017 ◽

Vol 35 (15_suppl) ◽

pp. LBA9007-LBA9007 ◽

Author(s):

Tony Mok ◽

Ying Cheng ◽

Xiangdong Zhou ◽

Ki Hyeong Lee ◽

Kazuhiko Nakagawa ◽

...

Keyword(s):

Egfr Mutation ◽

Phase Iii ◽

Small Cell Lung ◽

Phase Iii Trial ◽

Open Label Phase ◽

The full, final text of this abstract will be available at abstracts.asco.org at 7:30 AM (EDT) on Monday, June 5, 2017, and in the Annual Meeting Proceedings online supplement to the June 20, 2017, issue of the Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Download Full-text